Y-mAbs Therapeutics, Inc. Securities Lawsuit Investigation

On October 26, 2022, the FDA posted briefing documents regarding Y-mAbs’s (NASDAQ:YMAB) neuroblastoma drug, omburtamab, stating there were “significant questions” as to the adequacy and control of the submitted study. Previously, the company had received a Refusal to File letter from the FDA for omburtamab, leading Y-mAbs to resubmit its application for the drug on April 1, 2022.

Following this news of the FDA’s concerns, y-mAbs’s stock price dropped 23% on October 26, 2022, causing significant harm to investors.

Lost Money in Y-mAbs Stock?

You may be eligible to recover your losses. Get a free and confidential consultation.  

(Please provide number of shares, purchase date, and estimated losses.) 

loading...

Why is YMAB stock dropping?

On Wednesday, October 26, 2022, shares of Y-mAbs Therapeutics, Inc. dropped 27% after the FDA posted briefing documents regarding the company’s neuroblastoma drug, omburtamab, stating there were “significant questions as to whether the submitted study can be considered an adequate and well-controlled trial necessary to establish effectiveness.”

Previously, in y-mAbs’s earnings call for Q2 of 2022 on August 9, 2022, the company assured investors it had been involved in a number of “ongoing” discussions with the FDA regarding omburtamab and the team was “confident” they would be able to address any issues raised. The company further expressed, “given the fact that [neuroblastoma] is a rare disease, in an area of unmet medical need with very poor prognosis, we also believe the FDA…will look at this as an area where flexibility needs to be applied in making any judgments around risk benefit assessments.”

This is not the first set-back Y-mAbs has received for its drug omburtamab. In October of 2020, the FDA had issued a Refusal to File letter, leading Y-mAbs to resubmit its application for the drug on April 1, 2022.

Our Securities Lawyers Have a Winning Record Against Companies Like Y-mAbs Therapeutics

Our securities lawyers have recovered over a billion dollars on behalf of our clients against behemoths, such as Chase Bank, Mastercard, and Anthem Blue Cross Blue Shield. Read more about our results.

You “shouldn’t presume that powerful banks and other powerful interests can just get away with doing bad things. Good, qualified counsel that are committed to a cause can usually figure out how to prosecute such cases effectively and prevail.”

Eric Gibbs, award-winning securities attorney

titan of plaintiffs bar award
best law firm ranking
chambers USA leading firms award
daily journal top plaintiff lawyers award

Praise from the Courts

Federal judge in our AT&T class action:

“I’ve always found them to be extraordinary counsel in terms of their preparation and their professionalism.”

Federal judge in our Chase lawsuit (resulting in $100 million settlement):

They “fought tooth and nail, down to the wire” to achieve “the best settlement that they could under the circumstances.”

Read more about what judges say about us.

Our Featured Securities Team

Eileen Epstein Carney

Eileen represents investors and consumers harmed by financial fraud and other corporate misconduct. She also executes on the firm's strategic vision.

View full profile

Dave Stein

Dave represents clients in cases nationwide, ranging from securities and financial fraud cases to product liability, privacy, and data breach suits.

View full profile

Gibbs Law Group's Financial Fraud Experience

Gibbs Law Group’s financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).
california lawyer attorney of the year CLAY award
titan of plaintiffs bar award
best law firm ranking
chambers USA leading firms award
daily journal top plaintiff lawyers award